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Existing HIV treatment guidelines are updated
every two years by the International AIDS
Society1 and published in the Journal of the
American Medical Association. Consensus from
the Kaiser Foundation and Health and Human
Services on new agents are inserted on the
Guidelines Website as they become available
(www.hivaits.org; last update 5/99). 
A new version of the guidelines was recently pub-
lished in the Journal of the American Medical
Association.2 This article will review the new
guidelines and highlight important changes since
the last version was published 18 months ago
(1998). 
The July 1998 guidelines marked the codification
of "highly active antiretroviral therapy" (HAART),
a move that was supported by accumulating data
from clinical and pathogenesis studies. At the
time, there were a number of possible combina-
tion regimens available and an expanding num-
ber of choices for initial regimens. 
In updates published since 1998, Efavirenz
(Sustiva), Abacavir (Ziagen) and Amprenavir
(Agenerase) have been added to the list of possi-
ble treatment options. Now a total of 15 antiretro-
viral agents are available in the United States
(see Table 1). This underscores a guidelines rec-
ommendation that treatment of HIV-infected
patients should be directed by a physician with
extensive experience in the care of these
patients. 
The most significant difference between recom-
mendations from 1998 and the "state of ART" in
2000 should come as no surprise to correctional
HIV providers who have experience treating HIV
patients. The concept that we should "hit hard, hit
early" is evolving into "think hard, get the patient
involved, then hit hard as early as possible."
There are two reasons for the new hesitancy: (1)
side effects and (2) adherence. Indeed, when
the guidelines were written in 1998, protease
inhibitors were having a miraculous effect on
patients, and it appeared as if a cure for HIV was
at hand. Since then, an array of side effects asso-
ciated with HAART has been noted, and con-
cerns about the long-term durability of the new
drugs have been raised. 
Correctional clinicians must carefully weigh the
benefits of ART against the implications of long
term therapy. For our patients who commonly
experience destabilizing "life events," it becomes
increasingly important to identify factors that can
assist with stabilizing a patients’ life before initiat-
ing treatment. Thus, rehabilitation, education, and
careful discharge planning are increasingly
important components of expert HIV manage-
ment in corrections.
Revisiting "Hit Early, Hit Hard"
Initial theoretical modeling that HIV might be
eradicated after about three years of complete
viral suppression,3 have been withdrawn or
radically amended, as reports of viral rebound
after lengthy viral suppression accumulate.4
Unfortunately, the early speculative calculations
did not take into account the existence of a small
but critical pool of resting memory CD4+ lympho-
cytes that may contribute to persistence of repli-
cation-competent HIV in persons in spite of
maximal viral suppression.5, 6, 7
The good news is that there are few reports of
emergence of resistance when viral loads are
suppressed to 20 to 50 copies/mL, even though
most HIV researchers believe that viral replication
is ongoing at low levels in reservoir sites.
Furthermore, long-term suppression correlates
with durability of virologic response to potent reg-
imens.8,9,10
Adherence in the Real World
Even though patients are aware that close drug
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Correctional clinicians must care-
fully weigh the benefits of ART
against the implications 
of long term therapy.
adherence is essential in preventing viral
resistance, current regimens can be difficult
for patients to adhere to. Recognizing this, the
1998 guidelines stated that adherence, short-
term and long-term adverse effects, impact on
quality of life, and evolution of resistance must
be addressed with each person considering
treatment. The 2000 guidelines discern
advantages and disadvantages of each type
of triple drug regimen, highlighting regimens
that are easier to adhere to (see HIV 101,
pg. 8). 
Long term adverse drug effects
Over the past few years, HIV care providers
have been more concerned about the poten-
tial for long-term adverse drug effects.
Lipodystrophy continues to be a significant
side effect associated with protease inhibitors,
and new studies appear to indicate that this
condition may not be linked to any particular
drug, rather it may be linked to the duration of
therapy, to baseline body mass index, and to
the quantity of fat in the patients’ diet (for more
on these recent findings, see next month’s
HEPP News for a report on the 7th Retrovirus
conference). Reports of mitochondrial toxicity
(manifested by fatigue, nausea, vomiting,
abdominal pain, weight loss, dyspnea and low
serum bicarbonate levels) have been associ-
ated with the use of NRTIs (particularly D4T
and 3TC in one study of 106 cases by Boxwell
and Styrt, who reported the FDA experience
with mitochondrial toxicity at the 1999 ICAAC
meeting, Abstract 1284). However, physicians
who follow large numbers of incarcerated HIV-
infected patients on HAART have failed to
identify cases of severe mitochondrial toxicity
to date, even though low serum "bicarbonate"
is a frequent finding associated with treatment.
When to Initiate Therapy: 
Plan A/Plan B
The last time the guidelines were published,
there was growing recognition that early treat-
ment initiation was associated with virologic,
immunologic, and clinical benefits. Based on
that perception, the International AIDS
Society-USA panel recommends antiretroviral
therapy for any patient with established HIV
infection and a confirmed plasma HIV-1 RNA
level 5,000-30,000 copies/mL or T-cell count
350-500 copies/µL who "is committed to the
complex, long-term therapy" (see Table 2).
However, since the first therapeutic interven-
tion (Plan A) is the one with the greatest
chance of success, careful discussion of the
regimen with the patient is recommended. The
patient and physician should have another
plan (Plan B) in mind for future treatment
options, as well as some supplemental inter-
ventions (intensification) for the current regi-
men in case the initial regimen begins to falter. 
In addition to drug failure secondary to poor
adherence and suboptimal regimens, new
data has accumulated over the past year that
poor initial response may be due to pre-exist-
ing resistance to one or more of the selected
agents.11, 12 Genotyping at the time of treatment
initiation is gaining favor (see section
"Monitoring resistance" and Table 2, pg. 7).
Many would also consider therapy for patients
who have detectable viral loads at any level
and evidence of T-cell decline over time, how-
ever, there is a great deal of variation among
experienced practitioners. (See HIV 101 pg. 8
for a discussion of the options available at the
initiation of therapy.) 
HHS/IAS guidelines (Table 2) currently recom-
mend:
1. For asymptomatic patients with low plasma
HIV RNA level (e.g., <5000/mL) and high
CD4+ cell count (e.g., >350-500/µL) deferral
of therapy with close follow-up may be recom-
mended given treatment complexities, risk of
adverse effects, consequences of resistance,
and the possibility that such persons may fall
into the category broadly described as long-
term nonprogressor.
2. For those with moderately high HIV RNA
levels (e.g., 5,000-30,000 copies/mL) and low
CD4+ cell count (e.g. <350µL) therapy initia-
tion is recommended, given independent
prognostic significance of CD4+ cell count and
clinical trial data support.
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DRUG (Trade Name
& Manufacturer)
Zidovudine(AZT, ZDV)
(Retrovir)
Glaxo Wellcome
Didanosine (ddI) (Videx)
Bristol-Myers Squibb
Zalcitabine (ddC) (Hivid)
Roche
Lamivudine (3TC) (Epivir)
Glaxo Wellcome
Stavudine (d4T)(Zerit)
Bristol-Myers Squibb
Combivir (lamivudine +
zidovudine)
Glaxo Wellcome
Abacavir (Ziagen)
Glaxo Wellcome
Nevirapine  (Viramune
Boehringer/Roxane
Delavirdine (Rescriptor)
Pharmacia/Upjohn
Efavirenz (Sustiva)
Dupont Pharmaceuticals
Saquinvair (Inverase,
Fortovase)
Roche
Ritonavir (Norvir)
Abbott
Indinavir (Crixivan)
Merck
Nelfinavir (Viracept)
Agouron
Amprenavir  
(Agenerase)
Glaxo Wellcome
*Antiviral drug dosages are frequently updated. Consult the MMWR (Morbidity and  Mortality Weekly 
Report) for the most updated dosages (www.cdc.gov/mmwr).
1
30 minutes before or two hours after a meal.
Adapted from  Merigan T, Bartlett J, Bolognesis D.  Textbook of AIDS Medicine.  Second ed. Williams and Wilkins,
Baltimore MD. 1999. And HIV AIDS Treatment and Information Services: www.hivatis.org.
DOSAGE
300mg BID or 
200mg TID
200mg BID
or 400 QD
0.75mg TID
150mg BID
20 or 
40mg BID
1 tablet BID
300mg BID
200mg BID
see comments
400mg TID
600mg QD
Invirase:
3x200mg TID
Fortuvase:
6x200mg TID
600mg BID
800mg TID
(q8h)
750mg TID or
1250 mg BID 
1200mg BID
FORMULA-
TIONS
100mg
capsules
100mg
tablets
0.75mg
tablets
150mg
tablets
40mg
capsules
1 tablet
300mg
tablets
200mg
tablet
100mg
tablets
200mg
capsules
200mg
hard gelatin
capsules
200mg
hard gelatin
capsules
100mg
capsules
400mg
capsules
250mg
tablets
150mg
capsules
COMMENTS
Can cause anemia, neutropenia, nausea,
lethargy/confusion/agitation and myositis.
Take on empty stomach.1 Toxicities include
pancreatitis, peripheral neuropathy.
Peripheral neuropathy most common 
toxicity; also pancreatitis
Minimal toxicity; rapid resistance.
Can cause peripheral neuropathy
See comments under individual drugs
Rash, upper respiratory symptoms, 
muscle aches: flu-like syndrome that must
be carefully diagnosed - rechallenge may
lead to anaphylaxis and death.
Rapid resistance; good tissue penetration;
rash is common. Start with 200QDx14 
days then 200mg BID
Less experience; raises level of some 
protease inhibitors; rash less common than
with nevirapine: most would use in combi-
nation with other drugs as a "booster"
Vivid dreams, rash, diarrhea, headache
Poorly absorbed; should not be used 
as the only PI. Mild gastrointestinal 
disturbances common
Better absorbed than invirase, mild 
gastrointestinal disturbances common.
Gastorintestinal side effects common
TID dosing; take on empty stomach.1
Nephrolithiasis common; can be reduced
with adequate rehydration
May cause diarrhea; may induce less
cross-resistance
Most common side effects include nausea,
vomiting, diarrhea, rash, and tingling 
sensation around the mouth.
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
HIV Management... 
(continued from page 1)
Continued on page 4
Table 1. Current HIV Antiretrovirals and Dosages.*
Dear Colleagues,
Welcome to the February issue of HEPP News. You’ll note a number of important changes
in this issue. First, we are pleased to announce that Joe Bick of the California Department
of Corrections Medical Facility at Vacaville is joining Rick Altice and Anne De Groot as a
main editor. Lester Wright, Medical Director at the New York State Department of
Correctional Services, Joseph Paris, Medical Director of the Georgia Department of
Corrections, Khurram Rana, pharmacist at Roger Williams Hospital in Rhode Island, and
Ralf Jürgens of the Canadian AIDS Society have also joined the HEPP Advisory Board.
David Paar is now a Senior Advisor instead of an Associate Editor. All of us at HEPP would
like to thank Steve Szebenyi and Roderic Gottula, who are stepping down from the Advisory
Board, for all of their help and support this past year.
Second, we have received the results of our reader survey and we sincerely appreciate your
feedback. We are encouraged by the number of positive responses we received; according
to you, we meet your needs for HIV information that is corrections specific. In response to
your requests, we’ll be providing more "Ask the Expert" cases, alternating these cases with
Spotlights" on correctional HIV personalities or special programs.
Third, we hope you like the new "look" that our layout experts Michelle Gaseau and Kim
Backlund-Lewis of The Corrections Connection have provided.  
After reviewing this issue, readers should be able to chose the appropriate antiretroviral reg-
imens for either initiating or restarting therapy, identify which course of action to take given
a recidivist patient who had discontinued therapy, and describe the advantages and disad-
vantages of different antiretroviral therapy. In next month’s issue we will bring you news from
the 7th Conference on Retroviruses and Opportunistic Infections, as well as an update on
the treatment of tuberculosis in the correctional setting, edited by Joe Bick.
Give us your feedback! We like hearing from you.
Sincerely,
Anne  S. De Groot, M.D.
Letter from the Editor
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Therapeutic Caveats
It is important to note that dual NRTI and dual
PI regimens (without a third drug) are still not
considered acceptable forms of ART. Dual
NRTI regimens are not considered acceptable
except when encountering patients currently
succeeding on such a regimen. In those
cases, most HIV practitioners would not "rock
the boat" and would elect to keep the patient
on the dual NRTI treatment.
An increasing concern has been whether dis-
ease stage should dictate the approach to
treatment, since response rates decrease as
HIV disease advances. Many experienced
providers would consider using four drugs
instead of three for patients who were starting
therapy in later stage HIV/AIDS.
How to Start
The most important factors to consider when
first initiating a regimen include the following:
(1) the patient’s status (CD4+ T-cell count,
viral load); (2) the potency of the regimen; and
(3) the willingness and ability of the patient to
adhere to the regimen. Additional considera-
tions include the potential for drug interactions
with other necessary medications, the poten-
tial for exacerbation of underlying medical
conditions (e.g., neuropathy), the potential for
long-term adverse effects, and the preserva-
tion of future treatment options. The latter
point is worth keeping firmly in mind when dis-
cussing the initial regimen with the patient. A
well-designed Plan A (initial regimen) keeps
an equally effective and tolerable Plan B in
reserve. 
Monitoring Therapy Response
Beginning in 1998, the guidelines also fea-
tured a recommendation that quantitative viral
load assays be used to monitor therapeutic
response. The assays were considered "an
essential parameter" by the 1998 guidelines
panel and have become routine adjuncts to
the HIV management portfolio, even in correc-
tional settings. CD4+ T-cell counts have been
de-emphasized as a result, and now should be
followed at less frequent intervals (every three
to six months) after the initiation of therapy. 
A major advance in HIV treatment has been
the development of plasma HIV RNA assays
of increased sensitivity. These assays now
achieve a range of about 20-50 to about
50,000 copies/mL of plasma. Most physicians
obtain "Version 1" viral load measurements
(sensitive to about 400 copies/mL) about six
weeks to eight weeks after initiating therapy
(sooner if failure is considered possible) as the
first follow up indicator of response to a new
regimen.  If a response is seen, this is followed
by an "ultrasensitive" assay about two to four
weeks later. The expected response to an
effective regimen is reduction of viral load by
one log at eight weeks and no detectable virus
at four to six months after initiation. The more
rapid the reduction, the more effective the
therapy is believed to be. The ultra sensitive
assay confirms suppression of virus to   the
lowest detectable level and provides a bench-
mark for monitoring future response to thera-
py.
The rationale for tighter monitoring of viral
loads is that evolution of resistance is restrict-
ed in patients who have viral load levels less
than 50 copies/mL, even though low levels of
viral replication probably still persist. Evidence
of failing regimen includes: a decrease in
CD4+ T-cell count of greater than 30% from
baseline, and a greater than 0.5 log (or three-
fold) increase in viral load. As intercurrent
infections and vaccinations can affect viral
loads, measurements should be repeated
before instituting changes in therapy.
Monitoring Resistance and
Drug Levels
In 1998, both Genotyping and Therapeutic
Drug Level monitoring were thought to be
interesting but unproven; data now exists that
these tools are useful in some clinical settings
when implemented by fairly experienced HIV
providers. Note that drug resistance testing is
extremely costly. Resistance testing is best
used in combination with a careful drug histo-
ry to chose new regimens, since absence of
genotypic or phenotypic evidence of resis-
tance does not imply that a drug is guaranteed
to be active. Drug level monitoring is available
in some settings but will see limited use in  cor-
rectional settings due to cost and the absence
of good data showing better outcomes.
Treatment Failure:
Implementing Plan B
The strictest definition of treatment failure is
that of confirmed detectable plasma HIV RNA
(i.e., >50 copies/mL) in an adherent patient
who had achieved a viral load level below the
detection limit and has not experienced a
recent acute infectious illness or vaccination.
Indications for change include the following:
1. Less than a 0.5 to 0.75 log reduction of
plasma HIV RNA by four weeks following initi-
ation of therapy or less than a 1 log reduction
at eight weeks (intensification might be the
best option; see article by Rick Altice, MD in
the October 1999 issue of HEPP News);
2. Failure to suppress plasma HIV RNA to
undetectable levels within four to six months of
initiating therapy (except when the patient
starts  from a very high e.g. 106 viral load).
3. Repeated detection of virus after initial sup-
pression, suggesting viral resistance;
4. Any reproducible increase in the viral load
defined as three fold or greater that is not due
to acute intercurrent infectious illness or vacci-
nation;
5. Dual nucleoside therapy (if viral load not
undetectable). Note recommendation that all
patients be on at least triple drug regimens,
and note also that some clinicians would not
"rock the boat" as discussed above;
6. Persistently declining CD4+ T-cell numbers
as measured on at least two separate
occasions;
7. Clinical deterioration (bearing in mind that
some patients experience "reactivation" of
opportunistic infection, or "immune reconstitu-
tion syndrome" as their immune system recov-
ers with HAART).13, 14
For patients with their second or third regimen
failure, the decreasing number of options
remaining for the patient may dictate a more
conservative stance, with deferral of treatment
changes until   evidence of further increases in
HIV RNA level or decreases in CD4+ T-cell
count. Despite viral load increases, patients
continue to benefit from potent regimens even
after rebound viremia; for them, stopping ther-
apy may result in further viral load increase,
rendering re-establishment of adequate viral
suppression more difficult.15
Viral load/CD4 "disconnect"
Sometimes patients exhibit a discordant CD4+
decline in the face of continued viral load sup-
pression. In these cases, it is important to
examine the regimen for evidence of myelo-
toxic drugs (AZT, Hydroxyurea) and to contin-
ue to monitor. The pathogenic causes for dis-
cordant responses are uncertain. For those
with a confirmed CD4 cell decrease or con-
firmed rapid decrease, treatment changes
may be useful. 
Other Regimen Modifications
"Induction/maintenance" regimens are not
useful in the setting of HIV infection.
Furthermore, studies of patients who have dis-
continued therapy after prolonged adherence
to HAART and undetectable viral loads have
now repeatedly shown viral rebound, in some
cases to levels above the original set point.
Intensification
The practice of adding to, or intensifying an
existing regimen (reviewed by Dr. Rick Altice
in the October 1999 issue of HEPP News) is a
HIV Management... 
(continued from page 2)
Table 2. Ranges of CD4+ T-cell Count & Viral Load Levels for Therapy Initiation
Plasma HIV RNA Level, Copies/mL
CD4+ T-cells, 3x106/L <5,000 5,000-30,000 >30,000
<350 Recommend Recommend Recommend
Therapy Therapy Therapy
350-500 Consider Recommend Recommend
Therapy** Therapy Therapy
>500 Defer Consider Recommend
Therapy Therapy Therapy
**Opinions vary. Aggressive clinicians would treat patients at this level. Some choose to defer treatment.
Adapted from JAMA 1/19/00; 283(3): 382.
Continued on page 5
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Expert Response: Dr. Stephen Tabet, MD, MPH,*
When patients who have previously been on antiretrovirals enter the
prison system off their regimen, it is important to first determine why
the patient is no longer taking their medications. Generally, the rea-
sons incarcerated patients are off medications can be grouped into
four overlapping categories:
1. Non-adherence. Try to determine the reasons for poor adherence
and provide support to help the patient be more successful. One of the
biggest reasons that patients don’t take their medications once they
leave the correctional environment is because they don’t have link-
ages to care in the community; they simply stop taking their medica-
tions once they run out. Drug and alcohol use is clearly a strong com-
ponent in non-adherence. During incarceration, drugs and alcohol and
other competing outside interests are often less of an issue. A more
structured environment allows some patients to be more adherent.  
2. Drug intolerance. The patient may have stopped taking antiretrovi-
rals because of such common side effects as nausea or diarrhea that
were not treated.
3. Situation out of the patient’s control. When individuals are
arrested, they rarely have medications with them.  Many jails do not
allow others to bring patients their medications, or incarcerated per-
sons may not have access to someone who can bring in the medica-
tion and so they are discontinued on their regimen at the initial point of
incarceration.
4. Patient makes a conscious decision to temporarily stop taking
medications. Whether it is due to life circumstances outside the cor-
rectional system or the stress associated with reincarceration, some
individuals choose to hold off on medications until they are in a more
stable setting.
The next step is to determine whether the patient was on a failing anti-
retroviral regimen. When possible, patients on a failing regimen should
be started on an entirely new one as outlined in Table XVI of the
DHHS/Kaiser Guidelines (www.hivatis.org. Also see HEPPigram on
pg. 7). In actuality, it is often difficult to restart therapy, given prior treat-
ment failures and drug toxicities.  Patients with few good treatment
options can either be kept on their previous regimen, use a ’recycled’
regimen with previous medications, or even be placed on mega-
HAART regimens.
In this specific patient, I would initially start her on Pneumocystis carinii
pneumonia prophylaxis given that the CD4+ T-cells are below 200
cells/mL. Next, I would try to determine why the patient stopped her
medications. If the patient is going to be incarcerated for a short peri-
od (days) then I would likely recommend holding off on antiretrovirals
until she establishes care or returns to care in the community. I would
make sure she has medical and case management appointments
arranged prior to her leaving the institution. If the patient were going to
be incarcerated for the long-term, I would strongly recommend anti-
retrovirals since she has a low CD4 count.  
The next step is to determine the antiretroviral regimen. This individ-
ual, at least initially, tolerated the d4T, ddI, and efavirenz. If the patient
had tolerated her regimen and stopped all three antiretrovirals at once,
I would re-start the same regimen. I would follow her viral load closely
(one month and three month post-therapy to start) given that her virus
may already be resistant, especially to efavirenz. Otherwise, I would
discuss other regimens with her, avoid NNRTIs altogether, and offer
her two new NRTIs and at least one protease inhibitor.
*Grant Research/Support: Bristol-Myers Squibb and Merck Immune
Response Corp 
Ask the Expert
Case: A 28 year-old female offender returns to your facility having discontinued medication during her period of release. She was diagnosed
as HIV positive during her previous incarceration. She had been on ddI, D4T and efavirenz with no problems through her date of release. Her
old chart shows that she responded to the medication with a lower viral load from 15,000 to <50 copies/mL after eight weeks of therapy and
increased T-cell counts from 228 to 344. Her viral load is now 75,000 and her CD4 is dramatically lower (from 380 at release to 180 now). What
are your considerations when deciding how to proceed, and what treatment do you recommend now?
viable option in cases where the initial sup-
pression of viral load after the initiation of ther-
apy is less than adequate. For regimens
achieving satisfactory early HIV RNA declines,
but not below the limits of the most sensitive
assay available, addition of drug(s) to intensi-
fy the regimen may maximize long-term treat-
ment benefit. New drugs must be added
before viral rebound occurs; otherwise, addi-
tion of a single new drug can be viewed as
incremental therapy, which may promote
resistance. 
Plan B: What to Change to
When the decision is made to change therapy,
the approach should be guided by the reason
for the change. For adverse effects, intoler-
ance, or suboptimal adherence to an other-
wise successful regimen (i.e., HIV RNA level
below detection limits), selective substitution
of individual, identifiable offending compo-
nents is reasonable. When a change in thera-
py is indicated due to drug failure, the same
principles and considerations apply as
described previously. Efforts should be made
to change the regimen in its entirety, using
drugs with least potential for cross-resistance
to current drugs. (See Table 4 in the 2000
guidelines). We will address this issue at
greater length in a future issue of HEPP News.
Intermittent therapy
New findings show that intermittent interrup-
tion of anti-retroviral therapy appears to have
been beneficial. Some exposure to HIV primes
the immune response and may, in the long
run, be beneficial. Further studies16 of intermit-
tent interruption are underway. However,
some researchers feel that there are other
means of achieving immune stimulation in the
absence of viral replication. Therapeutic vacci-
nation is one such strategy (see HEPP News,
March 2000, Retrovirus Conference update ).
Budget Impact
While ART has been good news for patients
and their providers, one area of concern for
correctional budgeters has been the cost of
long-term therapy. Over the past few years,
researchers have published data that showed
that the use of potent therapy has resulted in
remarkable declines in hospitalization rates,
morbidity, and mortality where the drugs are
available.17-22 In community settings, protease
inhibitor (PI)-containing regimens were shown
to be cost-effective.23, 24
When to Stop Therapy
Eradication of HIV with maximally suppressive
therapy alone is unlikely given the present
understanding of HIV pathogenesis; thus,
therapy should be continued indefinitely. Even
with virologic failure, many patients maintain
clinical and immunologic benefit.25 After
attempts to adjust the drug regimen to sup-
press replication are made, therapy should be
continued in the face of virologic failure, if evi-
dence of clinical and immunologic stability
exists. In contrast, stopping all antiretroviral
therapy is reasonable when the patient, after
discussion with the physician, still believes
that the adverse effects outweigh potential
benefits of therapy.
Primary infection, post exposure prophylaxis,
and "Mega HAART" are also addressed by the
2000 guidelines, but will not be addressed
here. (For more information see
www.jama.org where the guidelines will be
accessible until the end of March, 2000). 
HIV Management... 
(continued from page 4)
Continued on page 6
University of Washington Division of Infectious Disease, Seattle HIVNET
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HEPPigram
Intake: inmate/patient 
meets criteria for ART.
Patient not currently on ART.
Continue ART
Check viral load.
Previously on ART
Wants ART Doesnt want ART
Measure baseline viral load
and CD4 T-cell counts.
Stopped ART due to 
significant side effects.
Select a new regimen, 
adding at least two new drugs 
to which expect minimal resistance.
Stopped ART because
although adherent, had 
virologic or clinical failure.
Stopped ART for
other reasons.
Has been off ART
for <2 weeks.
Restarting more urgent.
Restart same regimen
ASAP.
Restarting therapy less urgent.
Review medical records.
Review adherence (poor
adherence, side effects).
Carefully monitor viral load and
CD4 count, looking for possible 
failure. If poor response, 
consider genotyping and select
a new regimen.
Prior regimen suboptimal.
Select new regimen,
modify at least two drugs.
Prior regimen
optimal. Restart.
Has been off ART
for >2 weeks.
Educate
Educate, offer therapy
if appropriate
ART naïve
Patient currently on ART
with minimal (<7 days) disruption.
This decision tree was developed by HEPP Editors in order to describe how we restart
treatment for an HIV infected inmate who enters our facility off medications.  The pur-
pose of the tree is to provide a framework for discussion. Actual decisions regarding ART
are very complex and involve talking with patient and thoroughly discussing the treatment
options.  If readers have any suggestions as to how this tree might be modified, please
send your comments to Betsy Stubblefield at heppnews@brown.edu or fax
401.863.1243.
Proposed Decision Tree for Initiating or Restarting
Antiretroviral Therapy
In short, HIV management has transformed
dramatically over the past 20 years of the
epidemic. We’re now entering an age
where we have many therapeutic options
available to patients, and where careful
choice, and even more careful adherence
to a regimen, will determine the outcome of
a disease that should, in most cases,
resemble a chronic disease. See the March
HEPP News for additional updates from the
San Francisco Retrovirus meeting.
HIV Management... 
(continued from page 5)
* Consultant: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
Speakers Bureau: Agouron Pharmaceuticals, 
Bristol-Myers Squibb, Glaxo Wellcome
**Consultant: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
Speakers Bureau: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
***Speakers Bureau:  Agouron Pharmaceuticals,
Bristol-Myers Squibb, DuPont, Glaxo Wellcome,
Merck, Roche
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The 2000 National Conference on
African-Americans and AIDS
February 24-25, 2000
Renaissance Hotel, Washington DC
Call: 410.955.2959 
Fax: 410.955.0807
E-mail: cmenet@jhmi.edu
Visit: www.med.jhu.edu/cme
The Science and Treatment of HIV:
An Advanced CME Course for
Clinicians
March 25-29, 2000
Snowmass Village, CO
Call: 415.561.6725
Fax: 415.561.6740
E-mail: cme@iasusa.org
Visit: www.iasusa.org
Sponsor: International AIDS Society 
HIV Pathogenesis, Antiretrovirals,
and Other Selected Issues in HIV
Disease Management
February 26, Los Angeles, CA
March 8, Boston, MA
March 22, New York, NY
May date TBA, Dallas, TX
Call: 415.561.6725
Fax: 415.561.6740
E-mail: cme@iasusa.org
Visit: www.iasusa.org
Sponsor: International AIDS Society
National HIV/AIDS Update Conference
HIV/AIDS at the Crossroads:
Confronting Critical issues
March 14-17, 2000
San Francisco, CA
Call: 514.874.1998
Fax: 514.874.1580
E-mail nauc@total.net
Visit: www.nauc.org
Sponsor: AmFar
American Society of Clinical
Pathologists Teleconference
Update on Occupational Bloodborne
Disease Exposure: New Tests, New
Approaches to Prevention & Treatment
March 21, 2000  1pm CST
Call: 800.621.4142
Email: info@ascp.org
CME credit available.
National Conference on
Pharmaceutical Care to 
Underserved Populations
April 3-4, 2000
Chapel Hill, NC
Call: 919.966.8138
Email: steve_moore@unc.edu
Sponsors: School of Pharmacy and
Cecil Sheps Center for Health
Services Research, UNC at Chapel
Hill, HRSA, NC Assn of Pharmacists
CME available
HIV Prevention with 
Incarcerated Persons
A Public Health Training Network
Satellite Broadcast
April 27, 2000  1:00-3:00 PM EST
Call: 800.458.5231 or 
TTY 800.243.7012
Visit: www.cdcnpin.org/broadcast
Sponsor: CDC’s National 
Prevention Information Network
Save the 
Dates
News Flashes
Drug Warning for Abacavir Sulfate (Ziagen)
A revised warning concerning abacavir sulfate
(Ziagen) has been issued. Since its approval in
December 1998, the labeling for abacavir sulfate
has included a warning and description of fatal
hypersensitivity reactions to the drug. The new
warning emphasizes the importance of careful
consideration of abacavir sulfate patients who
have respiratory symptoms. Fatalities in patients
treated with abacavir sulfate who developed
hypersensitivity reactions including respiratory
symptoms of dyspnea, cough, or pharyngitis have
been reported. A delay in diagnosis of hypersen-
sitivity can result in abacavir sulfate being contin-
ued or re-introduced, leading to more severe
hypersensitivity reactions, such as life-threatening
hypotension and death. (See HEPPigram, April
1999 HEPP News). Cases of hypersensitivity
reaction should be reported to the Abacavir
Hypersensitivity Reaction Registry at Glaxo
Wellcome at 800-270-0425 or to the FDA
MedWatch program at 800-FDA-1088. 
Study Recommends Influenza Vaccine for
HIV- Infected Persons
Previous differing findings on the immunologic
and virologic effects of vaccination have caused
disparity in recommendations for influenza vacci-
nation. More recent studies involving HAART
treated persons document good antibody
responses in greater proportions of patients,
although the responses generally remain poor in
individuals with the lowest CD4+ cell counts. A
study by Salvato, et al., found that patients who
responded to antiretroviral therapy also respond-
ed well to influenza vaccine. Because of its cost
effectiveness, the authors recommend that
influenza should be part of routine prophylaxis for
HIV-positive persons. (Salvato, P. et al., AIDS
Reader, 12/99; 9(9):634-6291).
HAART May Reduce Genital Warts Despite HPV
In the December issue of the AIDS Reader,
Heard, et al., summarized their findings concern-
ing HAART and HPV. Cervical lesions respond
poorly to standard treatment and exhibit a high
recurrence rate in HIV-infected women. Despite
the persistence of HPV in women with advanced
HIV disease, HAART may provide a reduced
prevalence of cervical squamous intraepithelial
lesions. (Heard et al., AIDS Reader, 12/99;
9(9):630-635).
HIV Medication Still Compatible with Hepatitis
B or C
Hepatotoxicity, caused by the use of antiretroviral
drugs in treating HIV, prompted researchers to
evaluate the effects of the drugs in people with
Hepatitis B or C virus and attempt to determine
which drug combinations were more likely to
cause liver problems. The study included 298
patients who started new antiretroviral therapy
between January 1996 and January 1998, with 71
percent receiving protease inhibitors. The other
patients received dual NRTI regimens, the stan-
dard at that time. Overall, severe hepatotoxicity
was seen in about 10 percent of the patients. The
risk was greater for patients taking ritonavir; 30%
of patients on ritonavir experienced hepatotoxicity
versus only 8.1% of patients on other PIs. The
risks for nelfinavir, indinavir, and NRTI regimens
were similar and no deaths were associated with
the toxicity. The authors conclude that antiretrovi-
ral therapies should be given to HIV-infected
people who are infected with Hepatitis B or C.
(Sulkowski MS. JAMA 1/05/00; 283 (1) 74.) 
Supreme Court Denies Appeal of HIV Case
Last month the Supreme Court let stand a ruling
that allows Alabama prisons to segregate HIV-
positive inmates from the general prison popula-
tion during educational, vocational, recreational
and religious activities.  The court, without com-
ment, rejected an appeal filed on behalf of hun-
dreds of HIV-positive Alabama inmates that
argued the state’s policy violates federal laws pro-
tecting the disabled.  By rejecting the appeal, the
high court leaves intact an 11th U.S. Circuit Court
of Appeals ruling from last year that said the poli-
cy is valid "because HIV-positive inmates pose a
’significant risk’ to others." (New York Times,
1/18/00).
FDA Denies Accelerated Approval of Adefovir 
Adefovir (Preveon), the first nucleotide analogue
to be clinically evaluated for the treatment of HIV,
has been denied accelerated approval by the
Food and Drug Administration (FDA). This reverse
transcriptase inhibitor has been demonstrated to
be a potent antiretroviral in patients who have
failed zidovudine (ZDV) and lamivudine (3TC)
therapy. Despite its antiretroviral efficacy at 120
mg per day, adefovir has significant nephrotoxici-
ty (61%). Though trials using 60 mg per day are
under evaluation, the FDA was unable to deter-
mine adequate efficacy and safety using this
dose. At the present time, adefovir is no longer
available through its expanded access program.
(For more information, call 800-GILEAD-5 x1).
ACHSA 2000 Conference
The ACHSA 2000 Multidisciplinary Training
Conference was held in conjunction with ACA in
Phoenix, Arizona, and January 8-12, 2000. A
number of presentations were made concerning
HIV in corrections. In her presentation, Anne
Spaulding, MD suggested that HIV and HCV coin-
fected patients should be considered candidates
for therapy and not disqualified as in the past.
Joseph Paris, MD emphasized the dilemma pre-
sented to correctional managers: too many
denials of care may result in undertreatment,
inmate morbidity, and litigation. A weekly utiliza-
tion management system will ultimately fail
because of excessive health care costs. In a dif-
ferent presentation, Dr. Paris discussed the use of
all nucleoside regimens and the new non-nucleo-
side antiretrovirals that complement the previous-
ly available protease inhibitors in the correction
setting. Robert Greifinger, MD, presented a paper
describing efforts to lobby the Legislature towards
implementation of minimum correctional health
care standards. (For more information on the
conference, go to www.corrections.com/aca).
Contributed by: Joseph E. Paris, MD, SCP
President.
March HEPP News
Main Article: by Elsa Villarino, MD 
Discusses TB treatment in the correctional 
setting.
HIV 101: TB and HIV medications interactions
HEPPigram: PPD Testing Flow sheet
Ask the Expert: Discussion of TB and HIV 
coinfection
Plus updates from the 7th Conference on
Retroviruses and Opportunistic Infections.
Coming Next Month . . .
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1 Regimens for Initiating Antiretroviral Therapy:
Advantages and Disadvantages
REGIMEN
2 NRTIs* + PI*
2 NRTIs + NNRTI*
2 NRTIs + 2 PIs
3 NRTIs
NRTI + NNRTI + PI
Table adapted from JAMA 1/19/00; 283(3): 384  by Khurram Rana, Pharm D.
*NRTIs are nucleoside reverse transcriptase inhibitors.  NNRTIs are nonnucleoside reverse transcriptase inhibitors. PIs are protease inhibitors.
ADVANTAGES
Good to high potency
Clinical data
Combination with longest experience  
2 different "points of attack"
Good to high potency 
Defers protease inhibitor
Low pill burden
Acceptable to first line treatment
Less dietary restrictions
High potency
Convenient dosing
Less dietary restrictions
Defers exposure to protease inhibitor 
and NNRTI
Low pill burden
Low potential for drug interactions
High potency
3 "points of attack"
DISADVANTAGES
Complexity and high pill burden
May compromise future protease inhibitor regimens
Long-term toxicity
Some dietary restrictions
Potential for many P450 drug interactions
Limited long-term data
May compromise future NNRTI regimens
Potential P450 drug interactions (due to NNRTI)
High pill burden with some regimens
Long-term toxicities unknown
Potential P450 drug interactions (due to PI)
Limited data as initial regimen
Efficacy in patients with higher viral loads and lower
CD4 not yet determined
Limited long-term data
Compromises future NRTI regimens
Complexity
Compromises future regimens
Multiple-drug toxicity
Potential P450 drug interactions (due to PI)
Regimens Under Evaluation
Examples of combinations in current use for initial therapy include the following: (1) 1 PI and 2 NRTIs;  (2) 1 NNRTI and 2 NRTIs; (3)
2 PIs with 2 NRTIs; (4) 1 PI and 1 NNRTI with 1 or 2 NRTIs; and (5) 3 NRTIs. Regimen #4 is considered the least favorable option,
because of concerns about employing representatives of each of the 3 drug classes in an initial regimen; there is potential for mul-
tidrug-class resistance should the initial regimen fail.
Recently, regimen #1 (PI containing) and regimen #2 (PI sparing, NNRTI) were compared and found to be equivalent for the combina-
tions Indinavir/AZT/3TC and Efavirenz/AZT/3TC (see January HEPP Newsflash). Additional studies may be required before this regi-
men is implemented as first line treatment for patients with VL >100,000. Similarly, regimen #5 is a new option for those with baseline
viral load <500,000 that has done well in initial studies (Abacavir/AZT/3TC vs. Indinavir/AZT/3TC, see Newsflash in January HEPP
News, vol. 3 (1)).
Ryan White Title IV:  Grants for Coordinated HIV Services 
and Access to Research for Youth, Women, and Families
The Health Resources and Services Administration’s HIV/AIDS
Bureau (HRSA/HAB), announces the availability of funds for fiscal
year (FY) 2000 for discretionary grants to coordinate services and
provide medical care, support services and access to research for
HIV-infected and affected children, youth, women and families.To
obtain a full copy of this announcement, please go to
http://www.hrsa.gov/grantsf.htm
Application due date: March 1, 2000
Call: 877.477.2123
Fax: 877.477.2345
E-mail: hrsagac@hrsa.gov
Websites:
The Journal of the American Medical Association
http://www.jama.org
National Center for HIV, STD and TB Prevention, Divisions of
HIV/AIDS Prevention
http://www.cdcnpin.org/hiv/start.htm
7th Conference on Retroviruses and Opportunistic Infections
http://www.retroconference.org/
AEGIS-AIDS Education Global Information System
http://www.aegis.com
HIV Info Web, an on-line library containing HIV and AIDS-
related information, maintained online by the Massachusetts
DPH AIDS Bureau
http://www.infoweb.org
The Body: daily updated information on HIV/AIDS
http://www.thebody.com
The Corrections Connection
http://www.corrections.com
Treatment Related Websites:
CDC National Prevention Information Network
http://www.cdcnpin.org
The HIV/AIDS Treatment Information Service (ATIS)
http://www.hivatis.org
HIV/AIDS Treatment Directory 
http://www.amfar.org/td
Doctor’s Guide to the Internet: a straightforward guide to
internet medical resources
http://www.docguide.com
Resources
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through 
March  31, 2000.  The estimated time for completion of this activity is one hour and there is no fee for participation.
1.Which of the following parameters are relevant when initiating
anti-retroviral treatment?
a) Readiness to start
b) Stable life situation
c) CD4 T-cell count below 500
d) CD4 T-cell count rapidly declining
e) Viral load above 5000.
f) a and b 
g) b and c
h) All of the above
2. Which regimen is preferred for a treatment-naïve patient with a
viral load of 100,000 and a CD4 T-cell count of 250? 
a) Two PIs and an NNRTI
b) One NNRTI, one NRTI, and one PI
c) Two NRTIs and one PI
d) Two NNRTIs and one NRTI
e) Two NRTIs and one NNRTI
3. Which regimen is preferred for a treatment-naïve patient with a
viral load above 10,000 and a CD4 T-cell count of 450? 
a) Two PIs and an NNRTI
b) One NNRTI, one NRTI, and one PI
c) Two NRTIs and one PI
d) Two NNRTIs and one NRTI
e) Two NRTIs and one NNRTI
4. Which of the following regimens have the lowest pill and dose
burden? (More than one regimen may be correct.)
a) AZT/3TC (Combivir) and abacavir 
b) AZT/3TC (Combivir) and nelfinavir 
c) AZT/3TC (Combivir) and efavirenz 
d) DDI/D4T and efavirenz 
e) DDI/D4T and indinavir 
f) D4T/3TC and saquinavir 
5. Indicate the advantage(s) of using a regimen of 2 NRTIs and a
protease inhibitor instead of 2 NRTIs and an NNRTI.
a) The NNRTI containing regimen has a lower pill burden.
b) The protease inhibitor-containing regimen has a lower pill 
burden.
c) The NNRTI containing regimen has potential for many 
P450-drug interactions.
d) The protease inhibitor-containing regimen has less 
association with lipodystrophy.
6. At intake, a patient reports a history of ART, but he currently
does not take any medications. He would like to restart. What is
the next step?
a) Review viral load history.
b) Evaluate last regimen for adherence or access issues.
c) Take a careful medication history to find out how and 
when the medications were discontinued.
d) Try the former regimen and take a viral load and CD4 
count at four weeks.
e) Check viral load.
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Updates 5  4  3  2  1   5  4  3  2  1   
Save the 5  4  3  2  1   5  4  3  2  1   
Dates
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
February 2000     Volume 3, Issue 2 visit HEPP News online at www.hivcorrections.org 9
